ESMO E-Learning: Management of HER2-Low Breast Cancers by Paolo Tarantino
Paolo Tarantino shared a post on LinkedIn:
”Our understanding of HER2-low expression as a biomarker is rapidly evolving.
ESMO (European Society for Medical Oncology) has been at the forefront of providing guidance in this field, supporting the first Expert Consensus Guidelines and several further educational efforts.
The latest, a dedicated E-learning module on HER2-low (and ultralow) breast cancer.
Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023